Submitted:
23 January 2024
Posted:
24 January 2024
Read the latest preprint version here
Abstract
Keywords:
1. Introduction
2. Material and Methods
2.1. Patients and Study Design
2.2. Statistical analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
Ethics statement
References
- Paules, C.I.; Marston, H.D.; Bloom, M.E.; Fauci, A.S. Tickborne Diseases — Confronting a Growing Threat. New England Journal of Medicine 2018, 379, 701–703. [Google Scholar] [CrossRef] [PubMed]
- Kumar, A.; O’Bryan, J.; Krause, P.J. The Global Emergence of Human Babesiosis. Pathogens 2021, 10, 1447. [Google Scholar] [CrossRef] [PubMed]
- Meredith, S.; Oakley, M.; Kumar, S. Technologies for Detection of Babesia Microti: Advances and Challenges. Pathogens 2021, 10. [Google Scholar] [CrossRef]
- Asensi, J.M.; Martínez, A.M.; Guerrero, A.; Asensi, V.; Escudero, R.; de la Iglesia, P.; Arribas, J.M. Epidemiologic Study of Lyme Disease in Asturias. Available online: https://eurekamag.com/research/045/975/045975875.php (accessed on 6 April 2022).
- Espí, A.; Del Cerro, A.; Somoano, A.; García, V.; M. Prieto, J.; Barandika, J.F.; García-Pérez, A.L. Borrelia Burgdorferi Sensu Lato Prevalence and Diversity in Ticks and Small Mammals in a Lyme Borreliosis Endemic Nature Reserve in North-Western Spain. Incidence in Surrounding Human Populations. Enfermedades Infecciosas y Microbiología Clínica 2017, 35, 563–568. [Google Scholar] [CrossRef] [PubMed]
- Barreiro-Hurlé, L.; Melón-García, S.; Seco-Bernal, C.; Muñoz-Turrillas, C.; Rodríguez-Pérez, M. Seroprevalence of Lyme Disease in Southwest Asturias. Enfermedades infecciosas y microbiologia clinica (English ed.) 2020, 38, 155–158. [Google Scholar] [CrossRef] [PubMed]
- Almeida, H.; López-Bernús, A.; Rodríguez-Alonso, B.; Alonso-Sardón, M.; Romero-Alegría, Á.; Velasco-Tirado, V.; Pardo-Lledías, J.; Muro, A.; Belhassen-García, M. Is Babesiosis a Rare Zoonosis in Spain? Its Impact on the Spanish Health System over 23 Years. PLOS ONE 2023, 18, e0280154. [Google Scholar] [CrossRef] [PubMed]
- Asensi, V.; González, L.M.; Fernández-Suárez, J.; Sevilla, E.; Navascués, R.Á.; Suárez, M.L.; Lauret, M.E.; Bernardo, A.; Carton, J.A.; Montero, E. A Fatal Case of Babesia Divergens Infection in Northwestern Spain. Ticks and Tick-borne Diseases 2018, 9, 730–734. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, L.M.; Rojo, S.; Gonzalez-Camacho, F.; Luque, D.; Lobo, C.A.; Montero, E. Severe Babesiosis in Immunocompetent Man, Spain, 2011. Emerging Infectious Diseases 2014, 20, 724–726. [Google Scholar] [CrossRef] [PubMed]
- Langton, C.; Gray, J.; Waters, P.; Holman, P. Naturally Acquired Babesiosis in a Reindeer (Rangifer Tarandus Tarandus) Herd in Great Britain. Parasitology Research 2003, 89, 194–198. [Google Scholar] [CrossRef]
- Fanelli, A. A Historical Review of Babesia Spp. Associated with Deer in Europe: Babesia divergens/Babesia Divergens-Like, Babesia Capreoli, Babesia Venatorum, Babesia Cf. Odocoilei. Vet Parasitol 2021, 294, 109433. [Google Scholar] [CrossRef]
- Hildebrandt, A.; Zintl, A.; Montero, E.; Hunfeld, K.-P.; Gray, J. Human Babesiosis in Europe. Pathogens 2021, 10, 1165. [Google Scholar] [CrossRef] [PubMed]
- Krause, P.J. Concurrent Lyme Disease and Babesiosis: Evidence for Increased Severity and Duration of Illness. JAMA 1996, 275, 1657. [Google Scholar] [CrossRef] [PubMed]
- Svensson, J.; Hunfeld, K.-P.; Persson, K.E.M. High Seroprevalence of Babesia Antibodies among Borrelia Burgdorferi-Infected Humans in Sweden. Ticks and Tick-borne Diseases 2019, 10, 186–190. [Google Scholar] [CrossRef] [PubMed]
- Xi, D.; Thoma, A.; Rajput-Ray, M.; Madigan, A.; Avramovic, G.; Garg, K.; Gilbert, L.; Lambert, J.S. A Longitudinal Study of a Large Clinical Cohort of Patients with Lyme Disease and Tick-Borne Co-Infections Treated with Combination Antibiotics. Microorganisms 2023, 11, 2152. [Google Scholar] [CrossRef] [PubMed]
- Montero, E.; Folgueras, M.; Rodriguez-Pérez, M.; Pérez-ls, L.; Díaz-Arias, J.; Meana, M.; Revuelta, B.; Haapasalo, K.; Collazos, J.; Asensi, V.; et al. Retrospective Study of the Epidemiological Risk and Serological Diagnosis of Human Babesiosis in Asturias, Northwestern Spain. Parasites & Vectors 2023, 16. [Google Scholar] [CrossRef]
- Sweeney, C.J.; Ghassemi, M.; Agger, W.A.; Persing, D.H. Coinfection With Babesia Microti and Borrelia Burgdorferi in a Western Wisconsin Resident. Mayo Clinic Proceedings 1998, 73, 338–341. [Google Scholar] [CrossRef] [PubMed]
- Mylonakis, E. When to Suspect and How to Monitor Babesiosis. afp 2001, 63, 1969–1975. [Google Scholar]
- Krause, P.J.; Christianson, D.; Radolf, J.D.; Gadbaw, J.; Mckay, K.; Persing, D.; Lepore, T.; Sikand, V.; Closter, L.; Ryan, R.; et al. INCREASING HEALTH BURDEN OF HUMAN BABESIOSIS IN ENDEMIC SITES. The American Journal of Tropical Medicine and Hygiene 2003, 68, 431–436. [Google Scholar] [CrossRef] [PubMed]
- Moniuszko-Malinowska, A.; Swiecicka, I.; Dunaj, J.; Zajkowska, J.; Czupryna, P.; Zambrowski, G.; Chmielewska–Badora, J.; Żukiewicz-Sobczak, W.; Swierzbinska, R.; Rutkowski, K.; et al. Infection with Babesia Microti in Humans with Non-Specific Symptoms in North East Poland. Infectious Diseases 2016, 48, 537–543. [Google Scholar] [CrossRef]
- Cardenas-de la Garza, J.A.; De la Cruz-Valadez, E.; Ocampo-Candiani, J.; Welsh, O. Clinical Spectrum of Lyme Disease. European Journal of Clinical Microbiology & Infectious Diseases 2019, 38, 201–208. [Google Scholar] [CrossRef]
- Oteo, J.A.; Corominas, H.; Escudero, R.; Fariñas-Guerrero, F.; García-Moncó, J.C.; Goenaga, M.A.; Guillén, S.; Mascaró, J.M.; Portillo, A. Executive Summary of the Consensus Statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Spanish Society of Neurology (SEN), Spanish Society of Immunology (SEI), Spanish Society of Pediatric Infectology (SEIP), Spanish Society of Rheumatology (SER), and Spanish Academy of Dermatology and Venereology (AEDV), on the Diagnosis, Treatment and Prevention of Lyme Borreliosis. Enfermedades infecciosas y microbiologia clinica (English ed.) 2023, 41, 40–45. [Google Scholar] [CrossRef] [PubMed]
- González, L.M.; Castro, E.; Lobo, C.A.; Richart, A.; Ramiro, R.; González-Camacho, F.; Luque, D.; Velasco, A.C.; Montero, E. First Report of Babesia Divergens Infection in an HIV Patient. International Journal of Infectious Diseases 2015, 33, 202–204. [Google Scholar] [CrossRef] [PubMed]
- Delbecq, S.; Precigout, E.; Vallet, A.; Carcy, B.; Schetters, T.P.M.; Gorenflot, A. Babesia Divergens: Cloning and Biochemical Characterization of Bd37. Parasitology 2002, 125. [Google Scholar] [CrossRef]
- Vannier, E.; Krause, P.J. Human Babesiosis. New England Journal of Medicine 2012, 366, 2397–2407. [Google Scholar] [CrossRef]
- Vannier, E.G.; Diuk-Wasser, M.A.; Ben Mamoun, C.; Krause, P.J. Babesiosis. Infectious Disease Clinics of North America 2015, 29, 357–370. [Google Scholar] [CrossRef]
- Moro, M.H.; Zegarra-Moro, O.L.; Bjornsson, J.; Hofmeister, E.K.; Bruinsma, E.; Germer, J.J.; Persing, D.H. Increased Arthritis Severity in Mice Coinfected with Borrelia Burgdorferi and Babesia Microti. The Journal of Infectious Diseases 2002, 186, 428–431. [Google Scholar] [CrossRef]
- Boyer, P.H.; Lenormand, C.; Jaulhac, B.; Talagrand-Reboul, E. Human Co-Infections between Borrelia Burgdorferi S.l. and Other Ixodes-Borne Microorganisms: A Systematic Review. Pathogens 2022, 11, 282. [Google Scholar] [CrossRef]
- Wang, G.; Zhuge, J.; Wormser, G.P. Frequency of Positive Polymerase Chain Reaction (PCR) Testing for Borrelia Burgdorferi on Whole Blood Samples That Tested Positive for Babesia Microti by PCR from an Endemic Area for Both Infections in New York State. Pathogens 2023, 12, 1066. [Google Scholar] [CrossRef]
- Locke, S.; O’Bryan, J.; Zubair, A.S.; Rethana, M.; Moffarah, A.S.; Krause, P.J.; Farhadian, S.F. Neurologic Complications of Babesiosis, United States, 2011–2021. Emerging Infectious Diseases 2023, 29. [Google Scholar] [CrossRef]
- Stanek, G.; Wormser, G.P.; Gray, J.; Strle, F. Lyme Borreliosis. The Lancet 2012, 379, 461–473. [Google Scholar] [CrossRef]
- Rasoulzadeh, K.; Esmaeilnejad, B.; Dalir-Naghadeh, B.; Asri-Rezaei, S.; Tehrani, A.-A. Evaluation of Cardiovascular Biomarkers and Histopathological Alterations in Cattle Naturally Infected by Babesia Bigemina. Microbial Pathogenesis 2021, 161, 105275. [Google Scholar] [CrossRef] [PubMed]
- Bartnicki, M.; Łyp, P.; Dębiak, P.; Staniec, M.; Winiarczyk, S.; Buczek, K.; Adaszek, ł. Cardiac Disorders in Dogs Infected with Babesia Canis. Polish Journal of Veterinary Sciences 2017, 20, 573–581. [Google Scholar] [CrossRef] [PubMed]
- Odigie-Okon, E.G.; Okon, E.; Dodson, J.; Vorobiof, G. Stress-Induced Cardiomyopathy Complicating Severe Babesiosis. Available online: https://www.semanticscholar.org/paper/Stress-induced-cardiomyopathy-complicating-severe-Odigie-Okon-Okon/2c4210874b5be8030b8c7aceeceeb7018b6adf94 (accessed on 26 June 2023).
- Wroblewski, H.A.; Kovacs, R.J.; Kingery, J.R.; Overholser, B.R.; Tisdale, J.E. High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis. Antimicrobial Agents and Chemotherapy 2012, 56, 4495–4499. [Google Scholar] [CrossRef] [PubMed]
- Spichler-Moffarah, A.; Ong, E.; O’Bryan, J.; Krause, P.J. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2023, 76, e1385–e1391. [Google Scholar] [CrossRef] [PubMed]
| Monoinfected (n=73) |
Infected and with B. divergens IgG antibodies (n=47) |
P value | ||
|---|---|---|---|---|
| Demography & epidemiology | ||||
| - Gender | Male | 47 (64.4%) | 34 (72.3%) | 0.4 |
| Female | 26 (35.6%) | 13 (27.7%) | ||
| - Age years (n=119) | 58.0 (42.8-73.6) | 56.4 (45.5-71.8) | 0.8 | |
| - Occupation |
Farmer | 4 (8.5%) | 4 (12.1%) | 0.2 |
| Breeder | 3 (6.4%) | 2 (6.1%) | ||
| Open air activity | 0 (0%) | 3 (9.1%) | ||
| Other | 40 (85.1%) | 24 (72.7) | ||
| - Tick bite identified | Yes | 17 (24.6%) | 9 (20.9%) | 0.7 |
| No | 52 (75.4%) | 34 (79.1%) | ||
| - Tick removal | Yes | 12 (17.4%) | 8 (18.6%) | 0.9 |
| No | 57 (82.6%) | 35 (81.4%) | ||
| Predisposing factors | Yes | 66 (90.4%) | 42 (93.3%) | 0.7 |
| No | 7 (9.6%) | 3 (6.7%) | ||
| - Transfusion | Yes | 0 (0%) | 0 (0%) | - |
| No | 69 (100%) | 45 (100%) | ||
| - Asplenia | Yes | 0 (0%) | 0 (0%) | - |
| No | 69 (100%) | 45 (100%) | ||
| - Immunosuppression | Yes | 2 (2.9%) | 2 (4.4%) | 0.6 |
| No | 68 (97.1%) | 43 (95.6%) | ||
| - Age >50 years | Yes | 41 (57.7%) | 27 (60.0%) | 0.9 |
| No | 30 (42.3%) | 18 (40.0%) | ||
| - Outdoor hobbies | Yes | 45 (72.6%) | 34 (82.9%) | 0.2 |
| No | 17 (27.4%) | 7 (17.1%) | ||
| - Non-professional animal contact | Yes | 18 (29.0%) | 16 (39.0%) | 0.3 |
| No | 44 (71.0%) | 25 (61.0%) |
| Monoinfected (n=73) |
Infected and with B. divergens IgG antibodies (n=47) |
P value | ||
|---|---|---|---|---|
| SYMPTOMS | ||||
| - Duration of symptoms | days (n=92) | 7.0 (1.0-45.0) | 15.00 (6.00-105.0) | 0.11 |
| Constitutional symptoms | Yes | 15 (21.1%) | 10 (22.2%) | 0.9 |
| No | 56 (78.9%) | 35 (77.8%) | ||
| - Fever | Yes | 9 (12.7) | 5 (11.1%) | 0.8 |
| No | 62 (87.3%) | 40 (88.9%) | ||
| - Asthenia | Yes | 8 (11.3%) | 6 (13.3%) | 0.7 |
| No | 63 (88.7%) | 39 (86.7%) | ||
| - Anorexia | Yes | 2 (2.8%) | 0 (0%) | 0.5 |
| No | 69 (97.2%) | 45 (100%) | ||
| - Weight loss | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| Osteomuscular symptoms | Yes | 22 (31.0%) | 17 (37.8%) | 0.5 |
| No | 49 (69.0%) | 28 (62.2%) | ||
| - Arthralgias | Yes | 19 (26.8%) | 14 (31.1%) | 0.6 |
| No | 52 (73.2%) | 31 (68.9%) | ||
| - Arthritis | Yes | 12 (16.9%) | 5 (11.1%) | 0.4 |
| No | 59 (83.1%) | 40 (88.9%) | ||
| - Myalgias | Yes | 7 (9.9%) | 9 (20.0%) | 0.12 |
| No | 64 (90.1%) | 36 (80.0%) | ||
| Digestive symptoms | Yes | 3 (4.2%) | 0 (0%) | 0.3 |
| No | 68 (95.8%) | 45 (100%) | ||
| - Abdominal pain | Yes | 2 (2.8%) | 0 (0%) | 0.5 |
| No | 69 (97.2%) | 45 (100%) | ||
| - Nausea | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Vomiting | Yes | 1 (1.4%) | 0 (0%) | 1 |
| No | 70 (98.6%) | 45 (100%) | ||
| - Diarrhea | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| Cardiorespiratory symptoms | Yes | 4 (5.6%) | 9 (20.0%) | 0.02 |
| No | 67 (94.4%) | 36 (80.0%) | ||
| - Syncope | Yes | 1 (1.4%) | 2 (4.4%) | 0.6 |
| No | 70 (98.6%) | 43 (95.6%) | ||
| - Chest pain | Yes | 2 (2.8%) | 3 (6.7%) | 0.4 |
| No | 69 (97.2%) | 42 (93.3%) | ||
| - Dyspnea | Yes | 1 (1.4%) | 4 (8.9%) | 0.07 |
| No | 70 (98.6%) | 41 (91.1%) | ||
| - Palpitations | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| Neurologic symptoms | Yes | 33 (46.5%) | 25 (55.6%) | 0.3 |
| No | 38 (53.5%) | 20 (44.4%) | ||
| - Loss of strength | Yes | 11 (15.5%) | 9 (20.0%) | 0.5 |
| No | 60 (84.5%) | 36 (80.0%) | ||
| - Gait disturbance | Yes | 8 (11.3%) | 5 (11.1%) | 1 |
| No | 63 (88.7%) | 40 (88.9%) | ||
| - Cranial nerve involvement | Yes | 7 (9.9%) | 3 (6.7%) | 0.7 |
| No | 64 (90.1%) | 42 (93.3%) | ||
| - Paresthesia | Yes | 8 (11.3%) | 7 (15.6%) | 0.5 |
| No | 63 (88.7%) | 38 (84.4%) | ||
| - Dizziness | Yes | 3 (4.3%) | 2 (4.4%) | 1 |
| No | 67 (95.7%) | 43 (95.6%) | ||
| - Headache | Yes | 13 (18.3%) | 6 (13.3%) | 0.5 |
| No | 58 (81.7%) | 39 (86.7%) | ||
| - Hyperesthesia | Yes | 0 (0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| - Other symptoms | Yes | 9 (12.7%) | 4 (8.9%) | 0.5 |
| No | 62 (87.3%) | 41 (91.1%) | ||
| Ophthalmologic symptoms | Yes | 3 (4.2%) | 1 (2.2%) | 1 |
| No | 68 (95.8%) | 44 (97.8%) | ||
| - Photophobia | Yes | 2 (2.8%) | 1 (2.2%) | 1 |
| No | 69 (97.2%) | 44 (97.8%) | ||
| Cutaneous symptoms | Yes | 18 (25.4%) | 13 (28.9%) | 0.7 |
| No | 53 (74.6%) | 32 (71.1%) | ||
| - Erythema migrans | Yes | 14 (19.7%) | 8 (18.2%) | 0.8 |
| No | 57 (80.3%) | 36 (81.8%) | ||
| - Rash | Yes | 5 (7.0%) | 2 (4.4%) | 0.7 |
| No | 66 (93.0%) | 43 (95.6%) | ||
| - Other cutaneous involvement | Yes | 3 (4.2%) | 5 (11.1%) | 0.3 |
| No | 68 (95.8%) | 40 (88.9%) | ||
| Other symptoms | Yes | 9 (12.7%) | 1 (2.2%) | 0.09 |
| No | 62 (87.3%) | 44 (97.8%) | ||
| PHYSICAL EXAM | ||||
| General | Yes | 2 (2.8%) | 2 (4.4%) | 0.6 |
| No | 69 (97.2%) | 43 (95.6%) | ||
| - Jaundice | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Pharyngeal erythema | Yes | 0 (0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| - Lymphadenopathy | Yes | 2 (2.8%) | 2 (4.4%) | 0.6 |
| No | 69 (97.2%) | 43 (95.6%) | ||
| - Hepatomegaly | Yes | 0 (0.0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| - Splenomegaly | Yes | 0 (0.0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| Neurologic | Yes | 17 (23.9%) | 11 (24.4%) | 0.9 |
| No | 54 (76.1%) | 34 (75.6%) | ||
| - Meningeal signs | Yes | 2 (2.8%) | 0 (0%) | 0.5 |
| No | 69 (97.2%) | 45 (100%) | ||
| - Nystagmus | Yes | 2 (2.8%) | 0 (0%) | 0.5 |
| No | 69 (97.2%) | 45 (100%) | ||
| - Unilateral facial paralysis | Yes | 8 (11.3%) | 3 (6.7%) | 0.5 |
| No | 63 (88.7%) | 42 (93.3%) | ||
| - Bilateral facial paralysis | Yes | 2 (2.8%) | 1 (2.2%) | 1 |
| No | 69 (97.2%) | 44 (97.8%) | ||
| - Other cranial nerve involvement | Yes | 2 (2.8%) | 0 (0%) | 0.5 |
| No | 69 (97.2%) | 45 (100%) | ||
| - Romberg sign | Yes | 1 (1.4%) | 0 (0%) | 1 |
| No | 70 (98.6%) | 45 (100%) | ||
| - Babinski sign | Yes | 2 (2.8%) | 1 (2.2%) | 1 |
| No | 69 (97.2%) | 44 (97.8%) | ||
| - Muscle weakness | Yes | 12 (16.9%) | 7 (15.6%) | 0.8 |
| No | 59 (83.1%) | 38 (84.4%) | ||
| Ophthalmologic | Yes | 1 (1.4%) | 1 (2.2%) | 1 |
| No | 70 (98.6%) | 44 (97.8%) | ||
| - Retinal infarction | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Retinal hemorrhage | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Conjunctival hyperemia | Yes | 1 (1.4%) | 1 (2.2%) | 1 |
| No | 70 (98.6%) | 44 (97.8%) | ||
| TYPE OF LYME DISEASE | ||||
| - Early localized Lyme disease | Yes | 22 (31.9%) | 14 (31.1%) | 0.9 |
| No | 47 (68.1%) | 31 (68.9%) | ||
| - Early disseminated Lyme disease | Yes | 12 (17.4%) | 7 (15.6%) | 0.8 |
| No | 57 (82.6%) | 38 (84.4%) | ||
| - Late Lyme disease | Yes | 3 (4.3%) | 3 (6.7%) | 0.7 |
| No | 66 (95.7%) | 42 (93.3%) | ||
| - Past Borrelia infection | Yes | 21 (30.4%) | 16 (35.6%) | 0.6 |
| No | 48 (69.6%) | 29 (64.4%) | ||
| - Neurologic Lyme disease 1 | Yes | 12 (17.4%) | 7 (15.6%) | 0.8 |
| No | 57 (82.6%) | 38 (84.4%) | ||
| COMPLICATIONS | Yes | 0 (0.0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| - Respiratory distress | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Heart failure | Yes | 0 (0.0%) | 1 (2.2%) | 0.4 |
| No | 71 (100%) | 44 (97.8%) | ||
| - Disseminated intravascular coagulation | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Splenic infarct | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Splenic rupture | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| - Other complications | Yes | 0 (0%) | 0 (0%) | - |
| No | 71 (100%) | 45 (100%) | ||
| ALTERNATIVE DIAGNOSIS 2 | Yes | 21 (29.6%) | 15 (34.1%) | 0.6 |
| No | 50 (70.4%) | 29 (65.9%) |
| Monoinfected (n=73) |
Infected and with B. divergens IgG (n=47) |
P value | ||
|---|---|---|---|---|
| Chest X-ray | Normal | 38 (97.4%) | 26 (92.9%) | 0.6 |
| Abnormal | 1 (2.6%) | 2 (7.1%) | ||
| EGC | Normal | 36 (97.3%) | 27 (84.4%) | 0.09 |
| AV block | 1 (2.7%) | 5 (15.6%) | ||
| Laboratory blood determinations | ||||
| Total leukocyte counts | cells/μL (n=109) | 7500.0 (6165.0-9065.0) | 7240.0 (5612.5-9520.0) | 0.6 |
| Absolute neutrophil counts | cells/μL (n=109) | 4180.0 (3170.0-5765.0) | 4520.0 (2885.0-6552.5) | 0.8 |
| Absolute lymphocyte counts | cells/μL (n=107) | 1940.0 (1460.0-2590.0) | 1740.0 (1470.0-2307.5) | 0.3 |
| Absolute eosinophil counts | cells/μL (n=106) | 130.0 (77.5-232.5) | 135.0 (72.5-245.0) | 0.9 |
| Platelets | per μL (n=109) | 232000 (183000-294000) | 236000 (200250-285250) | 1 |
| Hemoglobin | gr/dL (n=109) | 14.10 (13.40-15.20) | 14.40 (13.38-15.23) | 0.8 |
| C-reactive protein | mg/L (n=89) | 0.350 (0.100-0.925) | 0.300 (0.100-1.400) | 0.7 |
| Erythrocyte sedimentation rate | mm/h (n=66) | 12.0 (4.8-22.0) | 11.0 (5.0-29.0) | 0.6 |
| Aspartate aminotransferase | U/L (n=37) | 24.0 (19.0-36.3) | 21.0 (20.0-28.0) | 0.9 |
| Alanine aminotransferase | U/L (n=93) | 19.0 (15.0-31.0) | 23.0 (17.0-28.0) | 0.2 |
| Lactate dehydrogenase | U/L (n=39) | 208.0 (182.0-237.0) | 207.0 (168.8-254.5) | 0.9 |
| Total bilirubin | mg/dL (n=73) | 0.90 (0.90-0.90) | 0.90 (0.90-0.90) | 0.3 |
| Alkaline phosphatase | U/L (n=89) | 73.0 (59.0-87.0) | 62.0 (52.5-83.3) | 0.2 |
| Creatinine | mg/dL (n=106) | 0.85 (0.74-1.02) | 0.80 (0.74-0.93) | 0.4 |
| Monoinfected (n=73) |
Infected and with B. divergens IgG (n=47) |
P value | ||
|---|---|---|---|---|
| Borrelia burgdorferi IgM serology | Positive | 43 (58.9%) | 27 (57.4%) | 0.9 |
| Negative | 30 (41.1%) | 20 (42.6%) | ||
| Borrelia burgdorferi IgG serology | Positive | 73 (100%) | 47 (100%) | - |
| Negative | 0 (0%) | 0 (0%) | ||
| Borrelia burgdorferi immunoblot | Positive | 62 (88.6%) | 39 (95.1%) | 0.5 |
| Negative | 1 (1.4%) | 0 (0%) | ||
| Doubtful | 7 (10.0%) | 2 (4.9%) | ||
| Babesia divergens indirect immunofluorescence assay | Positive | 0 (0%) | 47 (100%) | <0.0001 |
| Negative | 73 (100%) | 0 (0%) | ||
| Babesia divergens protein extract 1 | Positive | 0 (0%) | 40 (85.1%) | <0.0001 |
| Negative | 73 (100%) | 7 (14.9%) | ||
| Bd37 recombinant protein 1 | Positive | 0 (0%) | 15 (32 %%) | <0.0001 |
| Negative | 73 (100%) | 32 (68%) |
| Monoinfected (n=73) |
Infected and with B. divergens IgG (n=47) |
P value | ||
|---|---|---|---|---|
| Doxycycline | Yes | 21 (31.3%) | 19 (44.2%) | 0.17 |
| No | 46 (68.7%) | 24 (55.8%) | ||
| Doxycycline dosage | mg/day (n=39) | 200 (200-200) | 200 (200-200) | 0.3 |
| Amoxicillin | Yes | 5 (7.5%) | 5 (11.4%) | 0.5 |
| No | 62 (92.5%) | 39 (88.6%) | ||
| Amoxicillin dosage | mg/day (n=11) | 1500 (650-2625) | 1500 (938-2625) | 1 |
| Ceftriaxone | Yes | 10 (14.9%) | 7 (15.9%) | 9 |
| No | 57 (85.1%) | 37 (84.1%) | ||
| Ceftriaxone dosage | mg/day (n=17) | 1500 (1000-2000) | 2000 (1000-2000) | 0.8 |
| Cefuroxime | Yes | 1 (1.5%) | 0 (0%) | 1 |
| No | 66 (98.5%) | 44 (100%) | ||
| Azithromycin | Yes | 0 (0%) | 1 (2.2%) | 0.4 |
| No | 67 (100%) | 44 (97.8%) | ||
| Penicillin G | Yes | 1 (1.5%) | 0 (0%) | 1 |
| No | 66 (98.5%) | 44 (100%) | ||
| Treatment duration | weeks (n=108) | 2.00 (0.00-3.00) | 2.00 (0.00-3.00) | 0.7 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
